Company profile: Biomea Fusion
1.1 - Company Overview
Company description
- Provider of precision oncology and metabolic disease therapeutics based on novel covalent small molecules, including BMF-219, an oral investigational menin inhibitor for genetically defined cancers (AML, ALL, DLBCL, MM, CLL) and type 2 diabetes by enabling beta-cell proliferation and function; BMF-500, an investigational oral FLT3 inhibitor for AML; and the FUSION System, a platform for designing covalent small molecule therapies.
Products and services
- FUSION™ System: A proprietary platform that architects and develops novel covalent small-molecule therapies targeting high-value genetic drivers in cancer and metabolic diseases
- BMF-219: An oral covalent menin inhibitor that targets genetically defined cancers—AML, ALL, DLBCL, MM, CLL—and type 2 diabetes by enabling beta-cell proliferation and function
- BMF-500: An orally bioavailable covalent small-molecule FLT3 inhibitor engineered for treating AML and potentially in combination with other therapies, offering high potency and selectivity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Biomea Fusion
Indaptus Therapeutics
HQ: United States
Website
- Description: Provider of an immunotherapy platform leveraging attenuated and killed non-pathogenic gram-negative bacteria to activate innate and adaptive immune pathways for anti-tumor and anti-viral activity. Offers Decoy20, a Phase 1 therapeutic candidate using engineered bacteria to stimulate anti-tumor defenses, and an intravenous pipeline targeting cancers and infectious diseases with high unmet needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Indaptus Therapeutics company profile →
Medite Cancer Diagnostics
HQ: United States
Website
- Description: Provider of development, manufacture, and distribution as a mid-sized industrial corporation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medite Cancer Diagnostics company profile →
Five Prime Therapeutics
HQ: United States
Website
- Description: Provider of cancer treatment biotechnology, discovering and developing novel therapeutic proteins and antibodies by systematically screening all relevant human proteins to find the best for each clinical indication, enabled by its ProScreen Engine for rapid production and screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Five Prime Therapeutics company profile →
AroCell
HQ: Sweden
Website
- Description: Provider of biomarker-based diagnostic tests for cancer prognosis, monitoring, and follow-up, including the TK 210 ELISA measuring TK1 as a marker of increased cell turnover. Offers Oncology Diagnostics tools to capture critical clinical data for cancer patient management, and TUBEX TF, a rapid, sensitive in vitro test for detecting acute typhoid fever caused by Salmonella enterica.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AroCell company profile →
Northern Biologics
HQ: Canada
Website
- Description: Provider of state-of-the-art antibody discovery targeting novel and challenging oncology and fibrosis targets, developing therapeutic antibody candidates derived from a phage display platform developed and refined by world-leading researchers at the University of Toronto.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Northern Biologics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Biomea Fusion
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Biomea Fusion
2.2 - Growth funds investing in similar companies to Biomea Fusion
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Biomea Fusion
4.2 - Public trading comparable groups for Biomea Fusion
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →